Dergiler / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 6

Unsolved issues of the efficacy and safety of edoxaban

Sayfa
460–460
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

DRABİK, L., UNDAS, A. (2021). Unsolved issues of the efficacy and safety of edoxaban. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 6, 460–460. https://ajindex.com/articles/366630

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Liang X, Xie W, Lin Z, Liu M. The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis. Anatol J Cardiol 2021; 25: 77-88
  2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62. [Crossref] 3. Chen J, Zhuang X, Long M, Su C, Wang L. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. J Stroke Cerebrovasc Dis 2015; 24: 2710-9. [Crossref] 4. Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Pol Arch Intern Med 2020; 130: 47-58. [Crossref] 5. Lodziński P, Gawałko M, Budnik M, Tymińska A, Ozierański K, Grabowski M, et al. Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry. Pol Arch Intern Med 2020; 130: 196-205. [Crossref]